U.K. biotech company Harness Therapeutics has selected HRN001 as its lead experimental treatment candidate for Huntington’s disease. “The nomination of HRN001 represents a pivotal milestone for Harness and underscores our commitment to the Huntington’s disease community,” Jan Thirkettle, PhD, CEO of Harness, said in a company press…